BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24989436)

  • 41. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessing how reduced expression levels of the mismatch repair genes MLH1, MSH2, and MSH6 affect repair efficiency.
    Kansikas M; Kasela M; Kantelinen J; Nyström M
    Hum Mutat; 2014 Sep; 35(9):1123-7. PubMed ID: 24924810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation and management of Lynch syndrome.
    Boland CR
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):851,873. PubMed ID: 18185481
    [No Abstract]   [Full Text] [Related]  

  • 44. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
    Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clustering of Lynch syndrome malignancies with no evidence for a role of DNA mismatch repair.
    Case AS; Zighelboim I; Mutch DG; Babb SA; Schmidt AP; Whelan AJ; Thibodeau SN; Goodfellow PJ
    Gynecol Oncol; 2008 Feb; 108(2):438-44. PubMed ID: 18022218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
    Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
    Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
    Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel.
    O'Regan T; Chau K; Tatton M; Smith T; Parry S; Bissett I
    N Z Med J; 2013 Sep; 126(1382):70-7. PubMed ID: 24154771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.
    Bakry D; Aronson M; Durno C; Rimawi H; Farah R; Alharbi QK; Alharbi M; Shamvil A; Ben-Shachar S; Mistry M; Constantini S; Dvir R; Qaddoumi I; Gallinger S; Lerner-Ellis J; Pollett A; Stephens D; Kelies S; Chao E; Malkin D; Bouffet E; Hawkins C; Tabori U
    Eur J Cancer; 2014 Mar; 50(5):987-96. PubMed ID: 24440087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of endometrial cancer abnormal MMR protein in screening Lynch-syndrome families.
    Long Q; Peng Y; Tang Z; Wu C
    Int J Clin Exp Pathol; 2014; 7(10):7297-303. PubMed ID: 25400828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel MLH1 duplication identified in Colombian families with Lynch syndrome.
    Alonso-Espinaco V; Giráldez MD; Trujillo C; van der Klift H; Muñoz J; Balaguer F; Ocaña T; Madrigal I; Jones AM; Echeverry MM; Velez A; Tomlinson I; Milà M; Wijnen J; Carvajal-Carmona L; Castells A; Castellví-Bel S
    Genet Med; 2011 Feb; 13(2):155-60. PubMed ID: 21233718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity.
    Farrell MP; Hughes DJ; Drost M; Wallace AJ; Cummins RJ; Fletcher TA; Meany MA; Kay EW; de Wind N; Power DG; Andrews EJ; Green AJ; Gallagher DJ
    Fam Cancer; 2013 Dec; 12(4):741-7. PubMed ID: 23712482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Screening to detect Lynch syndrome and prevent hereditary cancers in relatives.
    Haddow JE; Palomaki GE
    J Med Screen; 2011; 18(4):167-8. PubMed ID: 22184732
    [No Abstract]   [Full Text] [Related]  

  • 58. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations.
    Joost P; Therkildsen C; Dominguez-Valentin M; Jönsson M; Nilbert M
    Urology; 2015 Dec; 86(6):1212-7. PubMed ID: 26385421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update on Lynch syndrome genomics.
    Peltomäki P
    Fam Cancer; 2016 Jul; 15(3):385-93. PubMed ID: 26873718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.